News Archives - ClinChoice https://clinchoice.co.jp/en/category/all-news/ The Standard of Excellence Mon, 23 Mar 2026 07:32:01 +0000 en-US hourly 1 https://wordpress.org/?v=7.1.3 https://clinchoice.co.jp/en/wp-content/uploads/2024/09/cropped-ico-1-32x32.png News Archives - ClinChoice https://clinchoice.co.jp/en/category/all-news/ 32 32 Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies! https://clinchoice.co.jp/en/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies/ https://clinchoice.co.jp/en/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies/#respond Mon, 23 Mar 2026 07:15:32 +0000 https://clinchoice.co.jp/en/?p=6136 MELBOURNE, Australia,March 23, 2026 — Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring groundbreaking health innovations and discoveries closer to patients worldwide.” Each organization brings distinct strengths to healthcare innovation, and both share a […]

The post Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies! appeared first on ClinChoice.

]]> MELBOURNE, Australia,March 23, 2026 —

Monash University and ClinChoice Inc, a leading global clinical Contract Research Organization (CRO) focused on innovative therapeutics, today announced a strategic partnership designed to fast-track early-phase clinical trials and bring groundbreaking health innovations and discoveries closer to patients worldwide.”

Each organization brings distinct strengths to healthcare innovation, and both share a clear commitment to improving health and wellbeing for patients around the world.

Picture Caption: Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise) (left), Kevin Xu, Chairman and CEO of ClinChoice (center), and Kerry Dyson, President, International Clinical Operations at ClinChoice (right), attended the signing ceremony to witness this milestone together.

Monash is a top 50 global university, and is Australia’s largest university with a global presence across the Indo-Pacific, Europe and the US.

The University is also part of Australia’s largest clinical trial network, spanning five major affiliated health services with more than 7,000 hospital beds and a national network of more than 3,000 GPs. Monash University-led trials account for around a quarter of all clinical trial activity in Australia, reaching a patient population of 4.5 million people.

The collaboration combines Monash University’s internationally recognized research excellence and clinical ecosystem with ClinChoice’s global development, regulatory and data science capabilities to support high‑quality, patient‑centric research across Australia and the broader international research landscape. A particular focus will be on accelerating early-phase clinical development and bringing innovative therapies to patients faster.

“Monash is deeply committed to pursuing impact-driven partnerships that leverage our expertise in research and healthcare innovation,” said Professor Robyn Ward AM, Deputy Vice-Chancellor (Research and Enterprise). “We’re proud to partner with ClinChoice. By combining our research excellence with their global capability, we can bring new therapies and technologies to patients while strengthening collaboration between our talented researchers with the global biotechnology sector.”

“We are honored to formalize this partnership with Monash University, a globally respected institution at the forefront of pharmaceutical science,” said Kevin Xu, Chairman and CEO of ClinChoice, “This collaboration is a strong testament to ClinChoice’s mission to support innovation through academic and clinical partnerships.”

“By combining our global development experience with Monash’s research excellence, we will advance clinical research in an even more efficient and impactful manner, ultimately bringing new therapies to patients faster,” added Kerry Dyson, President, International Clinical Operations at ClinChoice.

About Monash University


Monash University is one of Australia’s premier research-intensive universities and a globally recognized leader in pharmaceutical sciences and pharmacology.

The university ranks in the world’s top-50 universities in the QS World University Rankings 2026, QS Sustainability Rankings 2026 and US News and World Report (USNWR) Best Global Universities Rankings 2025-26. Monash has an international reputation for excellence in healthcare research and translation, and is ranked third internationally in Pharmacy and Pharmaceutical Sciences and fourth in Pharmacy and Pharmacology.

Through its world-renowned Monash Institute of Pharmaceutical Sciences (MIPS), Monash drives breakthrough innovations from target identification through preclinical and translational development. Consistently ranking among the top institutions worldwide for pharmacy and pharmacology, Monash plays a pivotal role in advancing novel therapeutics by integrating fundamental science with strong industry collaboration to translate research into real-world healthcare outcomes.

The university is home to the Monash Technology Precinct, bringing together researchers, industry partners and world-class facilities to drive collaboration and innovation – creating commercial opportunities and delivering meaningful benefits for communities.

About ClinChoice
ClinChoice is a global, clinical-stage CRO partnering with pharmaceutical and biotechnology companies to translate scientific innovation into clinical impact. With more than 30 years of experience and operations spanning over 15 countries across North America, Europe and Indo/Asia-Pacific, ClinChoice brings deep therapeutic expertise in hematology/oncology, immunology and inflammation (I&I), cardiometabolics and CNS. Having delivered more than 3,000 studies globally, ClinChoice has a strong track record of working with biopharmaceutical companies worldwide, and delivering early phase as well as late stage programs with speed, quality and innovation.

The post Monash University and ClinChoice Forge Strategic Partnership to Accelerate Clinical Development of Innovative Therapies! appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/monash-university-and-clinchoice-forge-strategic-partnership-to-accelerate-clinical-development-of-innovative-therapies/feed/ 0 Will be exhibiting at a booth at the 17th Annual Meeting of the Japanese Society of Clinical Trials from February 19th, 2026. https://clinchoice.co.jp/en/will-be-exhibiting-at-a-booth-at-the-17th-annual-meeting-of-the-japanese-society-of-clinical-trials-from-february-19th-2026/ https://clinchoice.co.jp/en/will-be-exhibiting-at-a-booth-at-the-17th-annual-meeting-of-the-japanese-society-of-clinical-trials-from-february-19th-2026/#respond Mon, 26 Jan 2026 06:12:04 +0000 https://clinchoice.co.jp/en/?p=6126 To be held at the Kobe International Conference Center from Thursday, February 19th to Saturday, February 21th, 2026 【will be exhibiting at the 17th Annual Meeting】 of the Japanese Society of Clinical Trials. We also have plenty of original merchandise prepared for you, so please feel free to stop by. Date: Thursday, February 19th, 2026 […]

The post Will be exhibiting at a booth at the 17th Annual Meeting of the Japanese Society of Clinical Trials from February 19th, 2026. appeared first on ClinChoice.

]]> To be held at the Kobe International Conference Center from Thursday, February 19th to Saturday, February 21th, 2026

【will be exhibiting at the 17th Annual Meeting】 of the Japanese Society of Clinical Trials.

We also have plenty of original merchandise prepared for you, so please feel free to stop by.

Date: Thursday, February 19th, 2026 – Saturday, February 21th, 2026

Venue: Kobe International Conference Center

3rd Floor,

Booth No. 23

Conference URL: https://jsctr17kobe.umin.jp/

The post Will be exhibiting at a booth at the 17th Annual Meeting of the Japanese Society of Clinical Trials from February 19th, 2026. appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/will-be-exhibiting-at-a-booth-at-the-17th-annual-meeting-of-the-japanese-society-of-clinical-trials-from-february-19th-2026/feed/ 0 Vietnam Regulatory Watch: Administrative Procedures, BE List Update, and Implementation Guidance – September 2025 https://clinchoice.co.jp/en/vietnam-regulatory-watch-september-2025/ https://clinchoice.co.jp/en/vietnam-regulatory-watch-september-2025/#respond Mon, 01 Sep 2025 06:05:15 +0000 https://clinchoice.co.jp/en/?p=6115 Welcome to the September 2025 edition. This month we focus on three developments that affect regulatory operations, dossier planning, and compliance across Vietnam’s drug market. We hope this update provides valuable insights into the evolving regulatory landscape in Vietnam. Should you require further details or assistance in navigating these changes, please do not hesitate to […]

The post Vietnam Regulatory Watch: Administrative Procedures, BE List Update, and Implementation Guidance – September 2025 appeared first on ClinChoice.

]]> Welcome to the September 2025 edition. This month we focus on three developments that affect regulatory operations, dossier planning, and compliance across Vietnam’s drug market.

1. MOH Decision 2546/QĐ-BYT (11 Aug 2025) — Administrative procedures consolidated

MOH announced newly issued/updated administrative procedures for the pharmaceutical domain. This aligns procedures with the 2025 pharmacy framework (e.g., Decree 163/2025 and Circular 31/2025) and gives provincial DOHs and DAV a common basis to organize implementation and public guidance.

Suggested actions:

  • Refresh internal SOPs and e-dossier checklists; map new forms/flows to your agents and MA holders.
  • Verify which submissions must move fully online vs. hybrid; clarify routing and receipt rules with DOHs.
  • Prepare a one-page explainer for commercial teams on what information must be disclosed online.

Official Source (Vietnamese): DAV news (MOH Decision 2546)

2.DAV Decision 409/QĐ-QLD (20 Aug 2025), DAV Decision 417/QĐ-QLD (28 Aug 2025) – Bioequivalence (BE) recognition list updated (Batch 9 and Batch 10)

DAV added medicines with BE evidence. The consolidated lists support registration strategies where BE data can be leveraged for abridged reviews or comparator alignment. Sponsors should audit in-flight dossiers and comparator choices against the latest batches.

Suggested actions:

  • Re-check BE-based routes and reference products; document any bridging rationale.
  • Update country files and Module 1 summaries to reference the latest BE batches where applicable.
  • For pipeline assets, build a matrix that maps molecules to available BE evidence/comparators.

Official Source (Vietnamese): DAV notice – BE List Batch 9, DAV notice – BE List Batch 10, DAV – Drug registration page

3. DAV Official Letter 2357/QLD-KD (15 Aug 2025) – Implementation guidance under the new pharmacy framework

This letter to provincial DOHs clarifies implementation of administrative procedures under recent regulations – responsibilities, document hygiene, and consistent handling of applications. Multiple provincial portals have reposted the letter and attachments, indicating roll-out momentum.

Suggested actions:

  • Engage local DOHs to confirm cut-over dates, submission modes, and any local checklists.
  • Run an internal readiness check (roles/RACI and Q&A) for affiliates/agents handling filings.
  • Create a tracker for clarifications issued by DOHs and DAV to keep teams aligned.

Official Source (Vietnamese): LuatVietnam

4. Ongoing quality & safety monitoring (late Aug)

DAV continues to publish quality/recall notices. Maintain batch-level surveillance with distributors and ensure recall SOPs align with Circular 30/2025.

Links:

We hope this update provides valuable insights into the evolving regulatory landscape in Vietnam. Should you require further details or assistance in navigating these changes, please do not hesitate to contact us.

The post Vietnam Regulatory Watch: Administrative Procedures, BE List Update, and Implementation Guidance – September 2025 appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/vietnam-regulatory-watch-september-2025/feed/ 0 Indonesia Regulatory Watch: A Primer on Drug Registration in Indonesia – August 2025 https://clinchoice.co.jp/en/indonesia-regulatory-watch-a-primer-on-drug-registration-in-indonesia-august-2025/ https://clinchoice.co.jp/en/indonesia-regulatory-watch-a-primer-on-drug-registration-in-indonesia-august-2025/#respond Tue, 12 Aug 2025 05:23:16 +0000 https://clinchoice.co.jp/en/?p=6109 Welcome to the August 2025 edition of our Indonesia Health Regulatory Update. This inaugural issue marks the beginning of a monthly series dedicated to exploring Indonesia’s pharmaceutical regulatory landscape. With a rapidly growing healthcare sector and one of the world’s largest populations, Indonesia presents a dynamic and growing pharmaceutical market. For companies seeking to register […]

The post Indonesia Regulatory Watch: A Primer on Drug Registration in Indonesia – August 2025 appeared first on ClinChoice.

]]> Welcome to the August 2025 edition of our Indonesia Health Regulatory Update. This inaugural issue marks the beginning of a monthly series dedicated to exploring Indonesia’s pharmaceutical regulatory landscape. With a rapidly growing healthcare sector and one of the world’s largest populations, Indonesia presents a dynamic and growing pharmaceutical market. For companies seeking to register drug products in Indonesia, understanding the regulatory framework is essential.

This month, we spotlight the critical regulatory steps and recent reforms that are reshaping drug registration in Indonesia. For companies entering this fast-evolving market, understanding these developments, and how to navigate them efficiently, is essential for strategic success.

1.Regulatory Authority: Badan Pengawas Obat dan Makanan (BPOM) and Its Role in Drug Oversight

BPOM is Indonesia’s central authority for regulating pharmaceuticals, traditional herbal medicines, cosmetics, and food products. BPOM is responsible for evaluating, approving, and monitoring all drug products distributed in the country.

Key functions include:

  • Product registration and evaluation
  • Post-market surveillance and pharmacovigilance
  • Good Manufacturing Practice (GMP) inspections and licensing
  • Public education and counterfeit prevention
2.Drug Registration Pathway: Key Steps and Requirements

All pharmaceutical products, whether imported or locally manufactured, must be registered with BPOM before commercialization. This includes ethical drugs, Over the counter (OTC) medicines, traditional and herbal products, and biologicals.

  • Step 1: Pre-Submission Preparation
    • Product classification: Determine whether the product is a new drug, generic, biologic, or traditional medicine.
    • Local representative: Foreign companies must appoint a local Indonesian agent or affiliate.
    • Document preparation: Includes administrative documents (e.g., Certificate of Pharmaceutical Product/CPP, GMP certificate), quality dossiers (e.g., Drug Master File), and clinical/non-clinical data. CPP refers to a certificate that approves the marketing of a pharmaceutical product, and GMP refers to a certificate that confirms compliance with manufacturing and quality control standards.
  • Step 2: Online Submission via BPOM Portal
    • Applications are submitted through BPOM e-Registration system.: e-Registration
    • Applicants choose one of three review pathways:
      • 100-days: For orphan drugs or urgent public health needs
      • 120-days: For drugs approved in reference countries (e.g., US, EU, Japan)
      • 300-days: Standard review for new drugs or major variations registration with new indications/posology
  • Step 3: Evaluation Process
    • Administrative screening: Ensures completeness and compliance.
    • Technical review: Assesses safety, efficacy, and quality.
    • GMP inspection: Required if the manufacturing site is not previously certified by BPOM.
  • Step 4: Clarifications and Supplementation
    • BPOM may request additional data or clarifications. Applicants typically have 120 days to respond.
  • Step 5: Marketing Authorization
    • Upon approval, BPOM issues a Nomor Izin Edar (NIE) – the official marketing authorization number, valid for 5 years and renewable upon re-evaluation.
  • Step 6: Post-Market Surveillance
    • Includes pharmacovigilance, sampling, advertising monitoring, and recalls if necessary.
3.Regulatory Trends and 2025 Outlook

In 2025, BPOM launched a Regulatory Development Program (Decision No. 278/2025) to revise and streamline regulations across pharmaceuticals, supplements, and cosmetics. While the initial focus has been on food and health supplements, the roadmap signals a broader push toward:

  • Digitalization of regulatory processes
  • Greater transparency and efficiency
  • Alignment with international standards (e.g., The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), ASEAN guidelines)
4. Common Challenges and Strategic Considerations

Companies entering the Indonesian market should be aware of several regulatory nuances:

  • Language requirements: Most documents must be submitted in Bahasa Indonesia.
  • Local clinical data: Required for certain product categories, especially new chemical entities.
  • Product classification: Misclassification can delay approval; early consultation with BPOM is recommended.

Strategic tip: Collaborating with experienced local partners can significantly reduce regulatory risk and accelerate market entry.

5. Looking Ahead

We hope this primer provides a useful starting point for navigating Indonesia’s pharmaceutical regulatory landscape. In our next issue, we will explore the structure and functions of BPOM in greater detail, including recent digital initiatives and organizational reforms.

If you are planning registration in Indonesia or considering ASEAN expansion, we are ready to support you with proven strategies tailored to BPOM’s current direction.

References：

Official Reference: Peraturan Menteri Kesehatan No. 1010/MENKES/PER/XI/2008 tentang Registrasi Obat

Traditional Medicine Definition: Putih dan Hijau Zaitun Modern Minimal Formal Laporan Media Sosial

The post Indonesia Regulatory Watch: A Primer on Drug Registration in Indonesia – August 2025 appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/indonesia-regulatory-watch-a-primer-on-drug-registration-in-indonesia-august-2025/feed/ 0 Vietnam Regulatory Watch: Drug Regulatory Reforms and E-Commerce Expansion – August 2025 https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-regulatory-reforms-and-e-commerce-expansion-august-2025/ https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-regulatory-reforms-and-e-commerce-expansion-august-2025/#respond Wed, 30 Jul 2025 07:35:38 +0000 https://clinchoice.co.jp/en/?p=6104 Welcome to our August 2025 Vietnam Health Regulatory Update. This month, we spotlight three key regulatory developments that are shaping the pharmaceutical landscape in Vietnam. These changes may offer both compliance challenges and strategic opportunities for Japanese pharmaceutical companies. We hope this update provides valuable insights into the evolving regulatory landscape in Vietnam. Should you […]

The post Vietnam Regulatory Watch: Drug Regulatory Reforms and E-Commerce Expansion – August 2025 appeared first on ClinChoice.

]]> Welcome to our August 2025 Vietnam Health Regulatory Update. This month, we spotlight three key regulatory developments that are shaping the pharmaceutical landscape in Vietnam. These changes may offer both compliance challenges and strategic opportunities for Japanese pharmaceutical companies.

1. New Circular 30/2025: Drug Quality Standards and Recall Procedures

Effective July 1, 2025, Circular No. 30/2025/TT-BYT replaces Circular 11/2018, bringing comprehensive updates to drug quality assurance and recall protocols.

Key updates include:

  • Recognition of Japanese Pharmacopoeia (JP): Companies may now use JP alongside other international pharmacopoeias (USP, EP, BP), providing enhanced flexibility in dossier preparation and product testing.
  • Electronic recall notification system: Mandatory reporting of substandard products through a centralized platform, with clearer timelines and responsibilities.。
  • Simplified processes for non-critical recalls, reducing disruption and improving risk-based management.

Official Source (Vietnamese): Government Portal – Circular 30/2025/TT-BYT on Drug Quality and Recall

2. Decree 163/2025 & Circular 31/2025: E-Commerce and Controlled Substances

These new provisions mark a significant shift in pharmaceutical distribution and compliance:

  • Legalization of pharmaceutical e-commerce: Online platforms can now sell drugs legally if they publicly display valid business licenses and pharmacy professional certifications.
  • Simplified destruction of controlled substances: Narcotics and psychotropics can now be destroyed with a 7-day advance notice, removing the need for prior MOH approval and easing operational burdens.

This opens up new commercial channels while requiring strict documentation transparency.

3. Amended Law on Pharmacy (Law 44/2024): Investment Incentives and Streamlined Registration

The amended Pharmacy Law introduces major reforms aimed at attracting investment and accelerating drug market access:

  • Pharma R&D and manufacturing designated as “priority sectors,” enabling access to tax incentives and land-use privileges for qualifying projects (≥ VND 3,000 billion / ~JPY 15 billion).
  • Shortened registration timelines: Supplementation is now limited to two rounds, with a third only in exceptional cases.
  • Simplified renewal applications if product quality has remained stable over the license term.

These changes aim to improve regulatory predictability for foreign manufacturers.

Official Source (Vietnamese): Government Portal – Law 44/2024/QH15 Amending the Law on Pharmacy

We hope this update provides valuable insights into the evolving regulatory landscape in Vietnam. Should you require further details or assistance in navigating these changes, please do not hesitate to contact us.

The post Vietnam Regulatory Watch: Drug Regulatory Reforms and E-Commerce Expansion – August 2025 appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-regulatory-reforms-and-e-commerce-expansion-august-2025/feed/ 0 Vietnam Regulatory Watch: Drug & Population Policy Updates – July 2025 https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-population-policy-updates-july-2025/ https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-population-policy-updates-july-2025/#respond Wed, 16 Jul 2025 04:59:01 +0000 https://clinchoice.co.jp/en/?p=6100 Welcome to our July 2025 Vietnam Health Regulatory Update. We are committed to keeping you informed about significant regulatory changes in Vietnam’s healthcare sector. Below are the key updates: 1. Abolition of Two-Child Policy and Introduction of Draft Population Law On June 3, 2025, Vietnam’s National Assembly approved amendments to the Population Ordinance, officially ending […]

The post Vietnam Regulatory Watch: Drug & Population Policy Updates – July 2025 appeared first on ClinChoice.

]]> Welcome to our July 2025 Vietnam Health Regulatory Update. We are committed to keeping you informed about significant regulatory changes in Vietnam’s healthcare sector. Below are the key updates:

1. Abolition of Two-Child Policy and Introduction of Draft Population Law

On June 3, 2025, Vietnam’s National Assembly approved amendments to the Population Ordinance, officially ending the longstanding two-child policy. This policy shift is in response to declining fertility rates, which fell to 1.91 children per woman in 2024, below the replacement level of 2.1. The Ministry of Health is concurrently drafting the country’s first Population Law, aiming to address demographic challenges such as aging population and regional population imbalances.

2. New Regulations on Drug Registration

On May 16, 2025, the Ministry of Health issued Circular No. 12/2025/TT-BYT, which will come into effect on July 1, 2025. This circular introduces significant changes to drug registration processes, including:

  • Abolishing the fixed list of over-the-counter (OTC) drugs, replacing it with a classification system based on specific criteria and methods.
  • Simplifying requirements for the Certificate of Pharmaceutical Product (CPP) by accepting a single CPP from recognized authorities.
  • Allowing submission of extension dossiers for marketing authorization at any time before expiry.
  • Limiting the number of supplementation rounds during the registration process to enhance efficiency.
  • Official Source (Vietnamese): DAV – Drug Administration of Vietnam (VN)

We hope this update provides valuable insights into the evolving regulatory landscape in Vietnam. Should you require further details or assistance in navigating these changes, please do not hesitate to contact us.

The post Vietnam Regulatory Watch: Drug & Population Policy Updates – July 2025 appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/vietnam-regulatory-watch-drug-population-policy-updates-july-2025/feed/ 0 Job Opportunities https://clinchoice.co.jp/en/job-opportunities-2/ https://clinchoice.co.jp/en/job-opportunities-2/#respond Fri, 09 May 2025 09:07:12 +0000 https://clinchoice.co.jp/en/?p=6092 Our recruitement information has been updated. Please access the Recruitment page for further details. ClinChoice K.K. is seeking the talents who want to work globally. You can choose from a varietical work styles in a our internationalcoporate culture. We look forward to receiving your application!

The post Job Opportunities appeared first on ClinChoice.

]]> Our recruitement information has been updated.

Please access the Recruitment page for further details.

ClinChoice K.K. is seeking the talents who want to work globally.

You can choose from a varietical work styles in a our internationalcoporate culture.

We look forward to receiving your application!

The post Job Opportunities appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/job-opportunities-2/feed/ 0 Job Opportunities https://clinchoice.co.jp/en/job-opportunities/ https://clinchoice.co.jp/en/job-opportunities/#respond Fri, 11 Apr 2025 07:28:27 +0000 https://clinchoice.co.jp/en/?p=6086 ClinChoice K.K. is always looking for the talented who want to make a global impact. Our international culture offers a variety of working styles. Please visit our Recruitment page for further details. We look forward to receiving your application! Jobs in ClinChoice Japan (採用情報)

The post Job Opportunities appeared first on ClinChoice.

]]> ClinChoice K.K. is always looking for the talented who want to make a global impact.

Our international culture offers a variety of working styles.

Please visit our Recruitment page for further details.

We look forward to receiving your application!

Jobs in ClinChoice Japan (採用情報)

The post Job Opportunities appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/job-opportunities/feed/ 0 ClinChoice Presents Webinar: Unfolding clinical development to China -Electronic data application in China- https://clinchoice.co.jp/en/clinchoice-presents-webinar-unfolding-clinical-development-to-china-electronic-data-application-in-china/ Wed, 09 Apr 2025 06:18:16 +0000 https://clinchoice.co.jp/en/?p=6084 We’d like to announce our webinar: Unfolding clinical development to China -Electronic data application in China-. As an advantage of ClinChoice Japan, which has one of its headquarters in China, we have prepared 2 topics regarding China electronic data application. We believe that those involved in application procedures will be interested. (Presentation language will be […]

The post ClinChoice Presents Webinar: Unfolding clinical development to China -Electronic data application in China- appeared first on ClinChoice.

]]> We’d like to announce our webinar: Unfolding clinical development to China -Electronic data application in China-.

As an advantage of ClinChoice Japan, which has one of its headquarters in China, we have prepared 2 topics regarding China electronic data application.

We believe that those involved in application procedures will be interested. (Presentation language will be Japanese)

<Event overview>

[Program] Unfolding clinical development to China -Electronic data application in China-

#1: Introduction to the guidelines for China electronic data application

#2: How to convert FDA-PMDA submitted data for NMPA

[Presenter] Hao Jin, Senior Manager, Statistical Programming, ClinChoice (Nanjing) Medical Technology Co.,Ltd

[Date and time] Tuesday, April 15, 2025, 17:30-18:30

[Location] Online (Microsoft Teams Webinar)

[Participation Fee] Free

[Registration URL] Please register from here ↓↓↓

https://events.teams.microsoft.com/event/33029883-2dff-4fd8-8ea6-a9dc8c24e84e@d4d2cdf1-c082-4167-839b-468cd007d351

Registration Deadline: April 14 (Mon) 18:00

If you have any questions or desire to know about the China Electronic Data Application, please fill them in upon your registration. We may reflect them in the contents if it’s along to the presentation.

We look forward to your participation!

Thank you.

The post ClinChoice Presents Webinar: Unfolding clinical development to China -Electronic data application in China- appeared first on ClinChoice.

]]> ClinChoice K.K. exhibited at the 16th Annual Meeting of the Japan Society of Clinical Trials and Research (JSCTR) https://clinchoice.co.jp/en/clinchoice-k-k-exhibited-at-the-16th-annual-meeting-of-the-japan-society-of-clinical-trials-and-research-jsctr/ https://clinchoice.co.jp/en/clinchoice-k-k-exhibited-at-the-16th-annual-meeting-of-the-japan-society-of-clinical-trials-and-research-jsctr/#respond Mon, 10 Mar 2025 05:54:43 +0000 https://clinchoice.co.jp/en/?p=6076 We perticipated as a booth exhibiter at the the 16th Annual Meeting of JECTR, held at Pacifico Yokohama from Friday, February 28 to Saturday, March 1, 2025. As a CRO who take a part in clinical trials and clinical research, we were introduced the various services we provide in the areas of statistical analysis, non-clinical […]

The post ClinChoice K.K. exhibited at the 16th Annual Meeting of the Japan Society of Clinical Trials and Research (JSCTR) appeared first on ClinChoice.

]]> We perticipated as a booth exhibiter at the the 16th Annual Meeting of JECTR, held at Pacifico Yokohama from Friday, February 28 to Saturday, March 1, 2025.

As a CRO who take a part in clinical trials and clinical research, we were introduced the various services we provide in the areas of statistical analysis, non-clinical and clinical trials for entering the Chinese market, and post-marketing surveillance.

We would like to express our gratitude to all the people who stopped by our booth.

The post ClinChoice K.K. exhibited at the 16th Annual Meeting of the Japan Society of Clinical Trials and Research (JSCTR) appeared first on ClinChoice.

]]> https://clinchoice.co.jp/en/clinchoice-k-k-exhibited-at-the-16th-annual-meeting-of-the-japan-society-of-clinical-trials-and-research-jsctr/feed/ 0